Pancreatic Cancer Research

ResearcherJichi Medical UniversityNo recent work listed

Akihiko Tsuchida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3970-3101; OpenAlex author ID A5038967664. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
94
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers

Papers 23

  1. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  2. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-bl… Co-author DOI 10.1186/s13063-021-05934-x↗
  3. Novel Therapeutic Method for Unresectable Pancreatic Cancer-The Impact of the Long-Term Research in Therapeutic Effect of High-Intensity Focused Ultrasound (HI… Co-author DOI 10.3390/curroncol28060409↗
  4. Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticodu… Last author DOI 10.1002/jhbp.725↗
  5. Clinical impact of pancreaticoduodenectomy for pancreatic cancer with resection of the secondary or later branches of the superior mesenteric vein. Last author DOI 10.1002/jhbp.789↗
  6. Safe exposure of the left renal vein during laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: anatomical variations and pitfalls. Last author DOI 10.1007/s00595-020-02053-z↗
  7. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. Co-author DOI 10.1007/s00535-018-1506-7↗
  8. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializi… Last author DOI 10.1245/s10434-018-07131-8↗
  9. Surgical Outcomes of Pancreaticoduodenectomy for Pancreatic Cancer with Proximal Dorsal Jejunal Vein Involvement. Last author DOI 10.1007/s11605-018-3722-0↗
  10. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer. Last author DOI 10.1159/000494382↗
  11. Irreversible Electroporation for Nonthermal Tumor Ablation in Patients with Locally Advanced Pancreatic Cancer: Initial Clinical Experience in Japan. Co-author DOI 10.2169/internalmedicine.0861-18↗
  12. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic … Last author DOI 10.1007/s00280-017-3288-7↗
  13. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Co-author DOI 10.1016/j.cca.2017.02.011↗
  14. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection. Last author DOI 10.1159/000449041↗
  15. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-B… Co-author DOI 10.1371/journal.pone.0161009↗
  16. Feasibility of intensity-modulated radiotherapy combined with gemcitabine and S-1 for patients with pancreatic cancer. Co-author DOI 10.3892/mco.2015.664↗
  17. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2014.623↗
  18. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Co-author DOI 10.1038/srep15921↗
  19. Pancreaticoduodenectomy with right-oblique posterior dissection of superior mesenteric nerve plexus is logical procedure for pancreatic cancer with extrapancre… Last author PMID 25699385↗
  20. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. Co-author DOI 10.1371/journal.pone.0046908↗
  21. Single nucleotide polymorphism of multidrug-resistance 1 and anti- multidrug-resistance 1 single chain antibody treatment for the pancreatic cancer cell line. First author DOI 10.5754/hge11377↗
  22. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism an… First author DOI 10.5754/hge11729↗
  23. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-10-0397↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichi Nagakawa · 16 shared papers, 2012–2022 · strength 1.21
  2. Yuichi Hosokawa · 8 shared papers, 2014–2020 · strength 0.59
  3. Sohei Satoi · 4 shared papers, 2019–2022 · strength 0.42
  4. Takao Itoi · 5 shared papers, 2012–2021 · strength 0.31
  5. Hitoe Nishino · 2 shared papers, 2020 · strength 0.23
  6. Tesshi Yamada · 6 shared papers, 2011–2017 · strength 0.21
  7. Takuji Okusaka · 6 shared papers, 2011–2017 · strength 0.21
  8. Kazufumi Honda · 6 shared papers, 2011–2017 · strength 0.21
  9. Tsutomu Fujii · 2 shared papers, 2019–2022 · strength 0.21
  10. Atsushi Sofuni · 3 shared papers, 2012–2021 · strength 0.20
  11. Shuji Isaji · 2 shared papers, 2019–2022 · strength 0.19
  12. Itaru Endo · 2 shared papers, 2019–2022 · strength 0.19
  13. Shoji Nakamori · 5 shared papers, 2011–2017 · strength 0.17
  14. Tomoo Kosuge · 5 shared papers, 2011–2017 · strength 0.17
  15. Tatsuya Ioka · 5 shared papers, 2011–2017 · strength 0.17
  16. Naohiro Sata · 5 shared papers, 2011–2017 · strength 0.17
  17. Masayuki Sho · 2 shared papers, 2019 · strength 0.17
  18. Michiaki Unno · 2 shared papers, 2019 · strength 0.17
  19. Kazuhiko Kasuya · 4 shared papers, 2012–2017 · strength 0.17
  20. Shuji Suzuki · 2 shared papers, 2018–2019 · strength 0.16
  21. Keiko Kamei · 1 shared paper, 2022 · strength 0.14
  22. Suguru Yamada · 1 shared paper, 2022 · strength 0.14
  23. Daisuke Hashimoto · 1 shared paper, 2022 · strength 0.14
  24. Tomohisa Yamamoto · 1 shared paper, 2022 · strength 0.14
  25. Kenichiro Uemura · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.